Skip to main content
Signal8

BNB PLUS CORP. (BNBX)

BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.

Sector: Finance Services

Industry: Biotechnology

BNB Plus Corp. logo

BNB Plus Corp.

OTC:BNBXOTC (suspended from Nasdaq on Jul 14, 2026)Healthcare
-6.17%$0.0760
Mkt Cap$568K
EV-
Float6.13M
O/S7.48M
VOL8K sh
$ Vol$600
RVOL0.92×
Inst Own0.0%
SI0.1%
Net Cash/Sh-
Dilution
BNB Plus Corp. logoOTC:BNBX$0.0760-6.17%

BNB PLUS CORP. (BNBX) dilution facts from SEC filings

Snapshot as of Jun 30, 2026, built from 49 SEC filings.

Shelf registration
None on file in the filings reviewed
At-the-market (ATM) program
Yes, sales agreement dated Nov 4, 2025
Source: 10-Q filed Aug 13, 2026
Warrants outstanding
12 warrant series recorded as outstanding
Most recent offering
Offering, priced Jul 23, 2026
Source: 10-Q filed Aug 13, 2026

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro